Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2007-12-19

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Treatment of HIV has come a long way since the discovery of the virus. Although no real cure has been found yet, the last few decades have seen the introduction of many classes of drugs that suppress the replication of the virus. As therapeutics have improved dramatically in terms of efficacy, safety and convenience, the bar for new drugs has been raised considerably.


Scope

  • In-depth analysis of Phase II and III clinical development compounds and comprehensive overview of Phase I drugs
  • Overview of the key companies involved in the HIV pipeline
  • The epidemiology dynamics of HIV in the six major markets are discussed along with unmet needs that have evolved from the prolonged use of HAART
  • Sales forecasts over the next 10 years for the each of the late-stage drugs


    • Report Highlights
    Class drug resistance represents a major problem for the NNRTIs. The two late stage compounds, developed by Tibotec/J&J, address this issue. etravirine is the more advanced of the two, but rilpivirine convenient dosing schedule makes it the commercially more promising candidate.

    New NRTIs in development have not generated much excitement in the HIV community since most of these compounds, including Avexa's apricitabine, Achillion's elvucitabine and Pharmasset's Racivir. have only made slow progress over the last few years.

    Historically, emerging drug resistance may have signaled overall treatment failure and hastened the onset of AIDS. While newer classes of drugs will enable patients with complex drug resistance to continue with successful antiretroviral therapy, exactly how they will be incorporated into traditional HAART regimens remains unclear at this stage.


    Reasons to Purchase

  • Understand the constantly evolving market dynamics of antiretroviral drugs
  • Understand the changing unmet needs of patients and the extent to which pipeline drugs are addressing these issues
  • Evaluate the forecast of key pipeline antiretroviral drugs to 2016, taking into account key launch dates, adressing of unmet needs and other factors

    • Table of Contents

    Other users found this report page using the following search terms: hiv nnrti haart nnrti structure hiv idx 899 pipeline mpc9055 novel chemical etravirine

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.